Patients on multiple daily injections (MDI) insulin therapy and Dexcom CGM saw greater A1C reduction than those on pump therapy and self-monitoring of blood glucose (SMBG).1
Medicare now provides coverage for therapeutic CGM systems (those approved for use in making diabetes treatment decisions). The Dexcom G5® Mobile CGM System is the first and only mobile-enabled CGM system covered as a Medicare benefit.
November is National Diabetes Awareness Month, a time when communities across the country bring attention to the impact and treatment of diabetes.
Listen now to the pre-recorded presentation and obtain CME credit.
Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.
Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.